SPECIALTY QUANTITY LIMIT PROGRAM

MAKENA (hydroxyprogesterone caproate) hydroxyprogesterone caproate (generic)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
hydroxyprogesterone caproate/Makena 250 mg/mL single dose vial (1 mL)	21 vials per 365 days	250 mg intramuscularly once weekly (every 7 days) Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first
hydroxyprogesterone caproate/Makena 250 mg/mL multi-dose vial (5 mL)	5 vials per 365 days	
Makena 275 mg/1.1 mL auto- injector	21 syringes per 365 days	275 mg subcutaneously once weekly (every 7 days) Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first

III. REFERENCES

- 1. Makena [package insert]. Waltham, MA: AMAG Pharmaceuticals; February 2018.
- 2. Hydroxyprogesterone caproate [package insert]. Shirley, NY. American Regent, Inc; July 2018.

Specialty Quantity Limit hydroxyprogesterone caproate-Makena 2978-H P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

